Home Trials Genes Drugs 23andMe Graph Blog Contact

Home
Trials
Genes
Drugs
23andMe
Graph
Blog
Contact

Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

ClinicalTrials.gov
OpenTargets
ClinVar
PubChem

Links

Contact
About
Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Indolent or Intermediate Grade B-cell Malignancy”

4 trials

Filters

Phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Status

Recruiting

Active, Not Recruiting

Not Yet Recruiting

Completed

Enrolling by Invitation

Showing 4 of 4 results

Testing effectiveness (Phase 2)WithdrawnNCT01263418

What this trial is testing

Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas

Who this might be right for

Lymphoma, Non-HodgkinLymphoma, FollicularLymphoma, B-Cell, Marginal Zone+2 more

UNC Lineberger Comprehensive Cancer Center

Testing effectiveness (Phase 2)Study completedNCT01206777

What this trial is testing

Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies

Who this might be right for

Indolent or Intermediate Grade B-cell Malignancy

Ohio State University Comprehensive Cancer Center 52

Testing effectiveness (Phase 2)WithdrawnNCT00004039

What this trial is testing

Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma

Who this might be right for

Hoag Memorial Hospital Presbyterian

Testing effectiveness (Phase 2)Active Not RecruitingNCT03749018

What this trial is testing

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Who this might be right for

Aggressive Non-Hodgkin LymphomaAnn Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaAnn Arbor Stage II B-Cell Non-Hodgkin Lymphoma+11 more

David Bond, MD 30